Focus on myeloproliferative diseases and myelodysplastic syndromes

Cancer Cell

Volumn 6, Issue 6, 2004, Pages 547-552

  Van Etten, Richard A ^a   Shannon, Kevin M ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ARSENIC TRIOXIDE; AZACITIDINE; CORTICOSTEROID; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LENALIDOMIDE; THALIDOMIDE;

CLINICAL FEATURE; DNA METHYLATION; HUMAN; MOLECULAR BIOLOGY; MUTATION; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 10944255947     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.12.004     Document Type: Review

References (52)

1. Araki T., Mohi M.G., Ismat F.A., Bronson R.T., Williams I.R., Kutok J.L., Yang W., Pao L.I., Gilliland D.G., Epstein J.A., Neel B.G. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 10:2004;849-857
2. Boocock G.R., Morrison J.A., Popovic M., Richards N., Ellis L., Durie P.R., Rommens J.M. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat. Genet. 33:2003;97-101
3. Braun B.S., Tuveson D.A., Kong N., Le D.T., Kogan S.C., Rozmus J., Le Beau M.M., Jacks T.E., Shannon K.M. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl. Acad. Sci. USA. 101:2004;597-602
4. Buonamici S., Li D., Chi Y., Zhao R., Wang X., Brace L., Ni H., Saunthararajah Y., Nucifora G. EVI1 induces myelodysplastic syndrome in mice. J. Clin. Invest. 114:2004;713-719
5. Chan I.T., Kutok J.L., Williams I.R., Cohen S., Kelly L., Shigematsu H., Johnson L., Akashi K., Tuveson D.A., Jacks T., Gilliland D.G. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J. Clin. Invest. 113:2004;528-538
6. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Lagare R.D., Cottes J., Kutok J., Clark J., Galinsky I., Griffin J.D., et al. A tyrosine kinase created by fusion of the PDGFA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348:2003;1201-1214. a
7. Cools J., Stover E.H., Boulton C.L., Gotlib J., Legare R.D., Amaral S.M., Curley D.P., Duclos N., Rowan R., Kutok J.L., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 3:2003;459-469. b
8. Correa P.N., Eskinazi D., Axelrad A.A. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro. studies in an improved serum-free medium Blood. 83:1994;99-112
9. D'Andrea A.D., Grompe M. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer. 3:2003;23-34
10. Dale D.C., Person R.E., Bolyard A.A., Aprikyan A.G., Bos C., Bonilla M.A., Boxer L.A., Kannourakis G., Zeidler C., Welte K., et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood. 96:2000;2317-2322
11. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 3:2003;11-22
12. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566
13. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341:1999;164-172
14. Gilliland D.G., Tallman M.S. Focus on acute leukemias. Cancer Cell. 1:2002;417-420
15. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:1994;307-316
16. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880
17. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 99:2002;319-325
18. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079-2088
19. Harada H., Harada Y., Tanaka H., Kimura A., Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood. 101:2003;673-680
20. Hoover R.R., Mahon F.-X., Melo J.V., Daley G.Q. Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood. 100:2002;1068-1071
21. Hu Y., Liu Y., Pelletier S., Buchdunger E., Warmuth M., Fabbro D., Hallek M., Van Etten R.A., Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. 36:2004;453-461
22. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., van Hoomissen I.C., Goldman J.M., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349:2003;1423-1432
23. Jamieson C.H.M., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., Gotlib J., Manz M.G., Keating A., Sawyers C.L., Weissman I.L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351:2004;657-667
24. Kantarjian, H.M., and Talpaz, M. eds. (2004). Chronic Myelogenous Leukemia. Hematol. Oncol. Clin. N. Am. 18, xv-xvi.
25. Klion A.D., Noel P., Akin C., Law M.A., Gilliland D.G., Cools J., Metcalfe D.D., Nutman T.B. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 101:2003;4660-4666
26. Kralovics R., Stocktonn D.W., Prchal J.T. Clonal hematpoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 102:2003;3793-3796
27. La Rosee P., Corbin A.S., Stoffregen E.P., Deininger M.W., Druker B.J. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62:2002;7149-7153
28. Landolfi R., Marchioli R., Kutti J., Gisslinger H., Tognoni G., Patrono C., Barbui T., ECLAP Investigators Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med. 350:2004;114-124
29. Lavau C., Du C., Thirman M., Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J. 19:2000;4655-4664
30. Le D.T., Kong N., Zhu Y., Lauchle J.O., Aiyigari A., Braun B.S., Wang E., Kogan S.C., Le Beau M.M., Parada L., Shannon K.M. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 103:2004;4243-4250
31. List A.F., Kurtin S., Glinsmann-Gibson B., Bellamy W., Buresh A., Mahadevan D., Rimsza L., Waddelton D., Knight R.D. Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes. Blood. 102:2003;184a
32. Loriaux M., Deininger M. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk. Lymphoma. 45:2004;2197-2203
33. Mohi M.G., Boulton C., Gu T.L., Sternberg D.W., Neuberg D., Griffin J.D., Gilliland D.G., Neel B.G. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. USA. 101:2004;3130-3135
34. Molldrem J.J., Komanduri K., Wieder E. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr. Opin. Hematol. 9:2002;503-508
35. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase myeloid leukemia. N. Engl. J. Med. 348:2003;994-1004
36. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., Paternoster S.F., Shearer B.M., Reeder T.L., Li C.Y., Cross N.C., Cools J., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 102:2003;3093-3096. a
37. Pardanani A., Reeder T., Porrata L.F., Li C.Y., Tazelaar H.D., Baxter E.J., Witzig T.E., Cross N.C., Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 101:2003;3391-3397. b
38. Reilly J.T. Idiopathic myelofibrosis. pathogenesis, natural history and management Blood Rev. 11:1997;233-242
39. Roumiantsev S., Krause D.S., Neumann C.A., Dimitri C.A., Asiedu F., Cross N.C.P., Van Etten R.A. Distinct stem cell myeloproliferative/T-lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 5:2004;1201-1214
40. Sattler M., Mohi M.G., Pride Y.B., Quinnan L.R., Malouf N.A., Podar K., Gesbert F., Iwasaki H., Li S., Van Etten R.A., et al. Essential role for Gab2 in transformation by BCR/ABL. Cancer Cell. 1:2002;479-492
41. Sawyers C.L., Denny C.T. Chronic myelomonocytic leukemia. Tel-a-kinase what ets all about Cell. 77:1994;171-173
42. Shah N.P., Tran C., Lee F.Y., Chen P., Norrris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 305:2004;399-401
43. Side L., Taylor B., Cayouette M., Connor E., Thompson P., Luce M., Shannon K. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Engl. J. Med. 336:1997;1713-1720
44. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., Stone R.M., Nelson D., Powell B.L., DeCastro C.M., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome. a study of the cancer and leukemia group B J. Clin. Oncol. 20:2002;2429-2440
45. Smith S.M., Le Beau M.M., Huo D., Karrison T., Sobecks R.M., Anastasi J., Vardiman J.W., Rowley J.D., Larson R.A. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia. The University of Chicago series Blood. 102:2003;43-52
46. Song W.J., Sullivan M.G., Legare R.D., Hutchings S., Tan X., Kufrin D., Ratajczak J., Resende I.C., Haworth C., Hock R., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia. Nat. Genet. 23:1999;166-175
47. Tartaglia M., Niemeyer C.M., Fragale A., Song X., Buechner J., Jung A., Hahlen K., Hasle H., Licht J.D., Gelb B.D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodisplastic syndromes and acute myeloid leukemia. Nat. Genet. 34:2003;148-150
48. Tartaglia M., Niemeyer C.M., Shannon K.M., Loh M.L. SHP-2 and myeloid malignancies. Curr. Opin. Hematol. 11:2004;44-50
49. Tefferi A. Chronic myeloid disorders. Classification and treatment overview Semin. Hematol. 38:2001;1-4
50. Temerinac S., Klippel S., Strunck E., Roder S., Lubbert M., Lange W., Azemar M., Meinhardt G., Schaefer H.-E., Pahl H.L. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood. 95:2000;2569-2576
51. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 100:2002;2292-2302
52. Zermati Y., De Sepulveda P., Feger F., Letard S., Kersual J., Casteran N., Gorochov G., Dy M., Ribadeau Dumas A., Dorgham K., et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 22:2003;660-664